Possible Future Avenues for Myositis Therapeutics: DM, IMNM and IBM
Overview
Affiliations
Idiopathic inflammatory myopathies (IIMs) represent a heterogeneous group of systemic autoimmune diseases characterized by immune-mediated muscle injury. As insights into pathogenesis of IIM evolve, novel therapeutic strategies have become available to optimize outcomes. Herein, we summarize novel and emerging strategies in the management of dermatomyositis (DM), immunemediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM).
Inclusion Body Myositis: A case report on navigating diagnostic challenges.
Al Sharji M, Al Busaidi S, Al Jahdhami S, Jawa Z, Farhan H, Al Alawi A Sultan Qaboos Univ Med J. 2024; 24(4):593-598.
PMID: 39634801 PMC: 11614014. DOI: 10.18295/squmj.6.2024.039.
IFNγ causes mitochondrial dysfunction and oxidative stress in myositis.
Abad C, Pinal-Fernandez I, Guillou C, Bourdenet G, Drouot L, Cosette P Nat Commun. 2024; 15(1):5403.
PMID: 38926363 PMC: 11208592. DOI: 10.1038/s41467-024-49460-1.
Inclusion body myositis, viral infections, and TDP-43: a narrative review.
Vacaras V, Vulturar R, Chis A, Damian L Clin Exp Med. 2024; 24(1):91.
PMID: 38693436 PMC: 11062973. DOI: 10.1007/s10238-024-01353-9.
Myopathy in systemic sclerosis.
Connolly C, Paik J Curr Opin Rheumatol. 2023; 35(6):341-348.
PMID: 37650694 PMC: 10538402. DOI: 10.1097/BOR.0000000000000966.
Clinical pearls and promising therapies in myositis.
Connolly C, Paik J Expert Rev Clin Immunol. 2023; 19(7):797-811.
PMID: 37158055 PMC: 10330909. DOI: 10.1080/1744666X.2023.2212162.